Research & Development

Research and Development

At OctaGenix, research and development is not just a department, it is the engine driving our mission to deliver transformative medicines to the people who need them most.

Our R&D Vision

We pursue innovation that is patient-centred, scientifically rigorous, and socially responsible. Every project is designed to increase access, reduce cost burdens, and improve outcomes for patients around the world.

Discovery & Early Innovation

We identify unmet medical needs, especially in Mental Health, Orphan Diseases, Biosimilars, and Rare Disorders and develop Research Products, Novel Generic or Special-Medicines solutions. Using state-of-the-art tools, including AI-driven compound screening, predictive modelling, and biomarker mapping, we accelerate the discovery of viable therapeutic candidates.

Clinical Development & Evidence Building

Our programs are designed to meet the highest standards of safety, efficacy, and regulatory compliance. We conduct rigorous preclinical and clinical studies, working with experienced CROs and academic partners. We generate evidence that supports regulatory approval, market access, and scalable treatment adoption.

Regulatory & Quality Excellence

Quality is foundational. Our R&D processes comply with MHRA, EMA, and other regulatory bodies’ requirements. From formulation development to manufacturing and safety monitoring, we maintain robust oversight to ensure that our products are safe, effective, and reliable.

Technology & Digital Innovation

We utilise emerging technologies; Organs-on-Chips technology, AI, machine learning, big data analytics to streamline discovery, optimise formulation and delivery, and predict patient response. These technologies also enable faster identification of promising molecules, improved safety profiling, and more efficient clinical trial design.

Partnerships & Collaboration

We believe breakthroughs happen together. OctaGenix® collaborates with universities, research institutes, healthcare systems, and patient groups. By sharing expertise and resources, we accelerate innovation and ensure our solutions meet real-world patient and clinical needs.

Next-Generation Therapeutic Platforms

Our work extends beyond molecules, we design advanced therapeutic platforms that enhance bioavailability, stability, and efficacy, turning complex or injectable treatments into scalable, patient-friendly solutions.

Our Achievements & Pipeline

At OctaGenix®, our research pipeline reflects our commitment to innovation, patient access, and tackling some of the most complex challenges in healthcare.

iSMART® Technology

We developed iSMART®, the world’s first and only AI-driven system capable of detecting viral carriers through body odour and changes in volatile organic compounds (VOCs). This breakthrough has the potential to transform infectious disease control and strengthen global public health responses.

Learn More

High-Cost, Low-Volume Therapies

We currently have more than five projects in active development within orphan therapeutics, biosimilars, and specialty generics. These programs target rare and underserved conditions where treatment options are limited, focusing on delivering effective and affordable solutions.

Learn More

Novel CNS Therapy - Ibogaine for PTSD

Our team has successfully formulated a low-dose ibogaine treatment for Post-Traumatic Stress Disorder (PTSD), which is now preparing to enter clinical trials. This pioneering therapy addresses an urgent unmet need for safer, more effective mental health interventions.

Learn More

Nicotine Replacement Therapy

We have obtained approvals from the MHRA, EMA, and other authorities for our Nicotine Replacement Therapy (NRT) product, launched as NOS®. This marks a key step in our mission to deliver cost-effective, next-generation smoking cessation tools that support public health.

Learn More

About us

Strategic View

Corporate Philosophy

Working for patients

Working for NHS